Fulcrum Therapeutics Stock Plummets 51% as Key Drug Program Terminated

In a move highlighting the high stakes for biotech firms with concentrated pipelines, Fulcrum Therapeutics stock sank 51% after terminating the development of its sickle cell disease drug, pociredir. The decision followed safety concerns raised by the U.S. Food and Drug Administration (FDA) regarding potential cancer risks associated with the treatment. Following the closure of this program, the company is left with no clinical-stage assets, casting significant doubt on its near-term pipeline viability.

This collapse places Fulcrum at a severe disadvantage compared to peers in the sickle cell space, such as Vertex Pharmaceuticals and Bluebird Bio, which secured landmark approvals for gene therapies in late 2023. Per market data, the failure of pociredir is a major setback for investors who viewed the drug as a potentially simpler oral alternative to complex gene editing procedures. Industry analysts note that the total loss of a clinical pipeline often forces small-cap biotech firms into radical restructuring or strategic mergers to survive.

Monitoring the stock's performance, FULC remains at depressed levels following the massive sell-off as of the close on June 3, 2026. Traders are now looking for any corporate guidance regarding cost-cutting measures or the acquisition of new assets to replenish the clinical pipeline. On the macro front, market participants are eyeing upcoming Swiss employment data and Italian business confidence reports on May 28, per the economic calendar, for broader cues on healthcare sector risk appetite.